Roche, Bristol On The Defensive After Merck's Lung Cancer Wins At ASCO

 
• By Emily Hayes

With Merck's Keytruda on top of the world and setting the standard for PD-1/L1 lung cancer data, Roche and Bristol defended the programs for their competing Tecentriq and Opdivo during ASCO investor events.

Rear view of businessman with suitcase looking at sunset above city

More from Immuno-oncology

More from Anticancer